Abstract
Original language | English |
---|---|
Pages (from-to) | 2684-2700 |
Number of pages | 17 |
Journal | Human brain mapping |
Volume | 44 |
Issue number | 7 |
Early online date | 2023 |
DOIs | |
Publication status | Published - 1 May 2023 |
Keywords
- frontotemporal dementia
- genetics
- magnetic resonance imaging
- neuropsychiatry
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Human brain mapping, Vol. 44, No. 7, 01.05.2023, p. 2684-2700.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia
AU - Bussy, Aurélie
AU - Levy, Jake P.
AU - Best, Tristin
AU - Patel, Raihaan
AU - Cupo, Lani
AU - van Langenhove, Tim
AU - Nielsen, J. rgen E.
AU - Pijnenburg, Yolande
AU - Waldö, Maria Landqvist
AU - Remes, Anne M.
AU - Schroeter, Matthias L.
AU - Santana, Isabel
AU - Pasquier, Florence
AU - Otto, Markus
AU - Danek, Adrian
AU - Levin, Johannes
AU - le Ber, Isabelle
AU - Vandenberghe, Rik
AU - Synofzik, Matthis
AU - Moreno, Fermin
AU - de Mendonça, Alexandre
AU - Sanchez-Valle, Raquel
AU - Laforce, Robert
AU - Langheinrich, Tobias
AU - Gerhard, Alexander
AU - Graff, Caroline
AU - Butler, Chris R.
AU - Sorbi, Sandro
AU - Jiskoot, Lize
AU - Seelaar, Harro
AU - van Swieten, John C.
AU - Finger, Elizabeth
AU - Tartaglia, Maria Carmela
AU - Masellis, Mario
AU - Tiraboschi, Pietro
AU - Galimberti, Daniela
AU - Borroni, Barbara
AU - Rowe, James B.
AU - Bocchetta, Martina
AU - GENetic Frontotemporal dementia Initiative (GENFI)
AU - Rohrer, Jonathan D.
AU - Devenyi, Gabriel A.
AU - Chakravarty, M. Mallar
AU - Ducharme, Simon
N1 - Funding Information: A. Bussy receives support from the Alzheimer Society of Canada. Dr Chakravarty is funded by the Weston Brain Institute, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, Healthy Brains Healthy Lives and Fondation de Recherches Santé Québec. Dr Ducharme received salary funding from the Fonds de Recherche du Québec - Santé. This work was also supported by the MRC UK GENFI grant (MR/M023664/1), the Italian Ministry of Health (CoEN015 and Ricerca Corrente), the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, a Canadian Institutes of Health Research operating grant, the Alzheimer's Society grant (AS-PG-16-007), the Bluefield Project and the JPND GENFI-PROX grant (2019–02248). MB is supported by a Fellowship award from the Alzheimer's Society, UK (AS-JF-19a-004-517). MB's work was also supported by the UK Dementia Research Institute which receives its funding from DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. JDR is an MRC Clinician Scientist (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198). Several authors of this publication (JCvS, MS, RSV, AD, MO, JDR) are members of the European Reference Network for Rare Neurological Diseases (ERN-RND) - Project ID No 739510. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Funding Information: This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Funding Information: Alzheimer Society of Canada; Weston Brain Institute; Fonds de Recherche du Québec ‐ Santé; MRC UK GENFI, Grant/Award Number: MR/M023664/1; Italian Ministry of Health, Grant/Award Number: CoEN015; Canadian Institutes of Health Research; Alzheimer's Society grant, Grant/Award Number: AS‐PG‐16‐007; Alzheimer's Society, Grant/Award Number: AS‐JF‐19a‐004‐517; NIHR Rare Diseases Translational Research Collaboration; Deutsche Forschungsgemeinschaft; NIHR Cambridge Biomedical Research Centre, Grant/Award Numbers: BRC‐1215‐20014, BRC149/NS/MH Funding information Funding Information: This work was also supported by the MRC UK GENFI grant (MR/M023664/1), the Italian Ministry of Health (CoEN015 and Ricerca Corrente), the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, a Canadian Institutes of Health Research operating grant, the Alzheimer's Society grant (AS‐PG‐16‐007), the Bluefield Project and the JPND GENFI‐PROX grant (2019–02248). MB is supported by a Fellowship award from the Alzheimer's Society, UK (AS‐JF‐19a‐004‐517). MB's work was also supported by the UK Dementia Research Institute which receives its funding from DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. JDR is an MRC Clinician Scientist (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198). Several authors of this publication (JCvS, MS, RSV, AD, MO, JDR) are members of the European Reference Network for Rare Neurological Diseases (ERN‐RND) ‐ Project ID No 739510. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy–ID 390857198). Funding Information: A. Bussy receives support from the Alzheimer Society of Canada. Dr Chakravarty is funded by the Weston Brain Institute, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, Healthy Brains Healthy Lives and Fondation de Recherches Santé Québec. Dr Ducharme received salary funding from the Fonds de Recherche du Québec ‐ Santé. Publisher Copyright: © 2023 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Recent studies have reported early cerebellar and subcortical impact in the disease progression of genetic frontotemporal dementia (FTD) due to microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72). However, the cerebello-subcortical circuitry in FTD has been understudied despite its essential role in cognition and behaviors related to FTD symptomatology. The present study aims to investigate the association between cerebellar and subcortical atrophy, and neuropsychiatric symptoms across genetic mutations. Our study included 983 participants from the Genetic Frontotemporal dementia Initiative including mutation carriers and noncarrier first-degree relatives of known symptomatic carriers. Voxel-wise analysis of the thalamus, striatum, globus pallidus, amygdala, and the cerebellum was performed, and partial least squares analyses (PLS) were used to link morphometry and behavior. In presymptomatic C9orf72 expansion carriers, thalamic atrophy was found compared to noncarriers, suggesting the importance of this structure in FTD prodromes. PLS analyses demonstrated that the cerebello-subcortical circuitry is related to neuropsychiatric symptoms, with significant overlap in brain/behavior patterns, but also specificity for each genetic mutation group. The largest differences were in the cerebellar atrophy (larger extent in C9orf72 expansion group) and more prominent amygdalar volume reduction in the MAPT group. Brain scores in the C9orf72 expansion carriers and MAPT carriers demonstrated covariation patterns concordant with atrophy patterns detectable up to 20 years before expected symptom onset. Overall, these results demonstrated the important role of the subcortical structures in genetic FTD symptom expression, particularly the cerebellum in C9orf72 and the amygdala in MAPT carriers.
AB - Recent studies have reported early cerebellar and subcortical impact in the disease progression of genetic frontotemporal dementia (FTD) due to microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72). However, the cerebello-subcortical circuitry in FTD has been understudied despite its essential role in cognition and behaviors related to FTD symptomatology. The present study aims to investigate the association between cerebellar and subcortical atrophy, and neuropsychiatric symptoms across genetic mutations. Our study included 983 participants from the Genetic Frontotemporal dementia Initiative including mutation carriers and noncarrier first-degree relatives of known symptomatic carriers. Voxel-wise analysis of the thalamus, striatum, globus pallidus, amygdala, and the cerebellum was performed, and partial least squares analyses (PLS) were used to link morphometry and behavior. In presymptomatic C9orf72 expansion carriers, thalamic atrophy was found compared to noncarriers, suggesting the importance of this structure in FTD prodromes. PLS analyses demonstrated that the cerebello-subcortical circuitry is related to neuropsychiatric symptoms, with significant overlap in brain/behavior patterns, but also specificity for each genetic mutation group. The largest differences were in the cerebellar atrophy (larger extent in C9orf72 expansion group) and more prominent amygdalar volume reduction in the MAPT group. Brain scores in the C9orf72 expansion carriers and MAPT carriers demonstrated covariation patterns concordant with atrophy patterns detectable up to 20 years before expected symptom onset. Overall, these results demonstrated the important role of the subcortical structures in genetic FTD symptom expression, particularly the cerebellum in C9orf72 and the amygdala in MAPT carriers.
KW - frontotemporal dementia
KW - genetics
KW - magnetic resonance imaging
KW - neuropsychiatry
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85150648466&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36895129
U2 - https://doi.org/10.1002/hbm.26220
DO - https://doi.org/10.1002/hbm.26220
M3 - Article
C2 - 36895129
SN - 1065-9471
VL - 44
SP - 2684
EP - 2700
JO - Human brain mapping
JF - Human brain mapping
IS - 7
ER -